Uprevstobart Biosimilar – Anti-CD73 mAb – Research Grade

Description of Uprevstobart Biosimilar - Anti-CD73 mAb - Research Grade

Uprevstobart Biosimilar – Anti-CD73 mAb is a monoclonal antibody that has been developed as a biosimilar to the well-known therapeutic antibody, Uprevstobart. This biosimilar is specifically designed to target CD73, a protein that is highly expressed in various types of cancer and has been identified as a potential therapeutic target. In this article, we will discuss the structure, activity, and potential applications of Uprevstobart Biosimilar – Anti-CD73 mAb.

Uprevstobart Biosimilar – Anti-CD73 mAb is a recombinant humanized IgG1 monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains consist of four constant regions (CH1, CH2, CH3, and CH4) and one variable region (VH), while the light chains consist of one constant region (CL) and one variable region (VL). The variable regions of both the heavy and light chains are responsible for binding to the target protein, CD73.

The amino acid sequence of Uprevstobart Biosimilar – Anti-CD73 mAb is highly similar to that of Uprevstobart, with only a few differences in the constant regions. This ensures that the biosimilar has a similar structure and function to the original therapeutic antibody.

The main activity of Uprevstobart Biosimilar – Anti-CD73 mAb is to bind to CD73, a cell surface protein that is involved in the conversion of extracellular adenosine monophosphate (AMP) to adenosine. This process is important for regulating various physiological processes, including immune response, inflammation, and tumor growth.

By binding to CD73, Uprevstobart Biosimilar – Anti-CD73 mAb blocks its activity and prevents the conversion of AMP to adenosine. This leads to an increase in extracellular AMP levels, which has been shown to have anti-tumor effects. Additionally, the binding of the biosimilar to CD73 also leads to antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further contribute to its anti-tumor activity.

Uprevstobart Biosimilar – Anti-CD73 mAb has shown promising results in preclinical studies for the treatment of various types of cancer, including breast, lung, and colon cancer. It has also been shown to enhance the efficacy of other anti- cancer therapies, such as chemotherapy and immune checkpoint inhibitors.

In addition to its potential as a cancer treatment, Uprevstobart Biosimilar – Anti-CD73 mAb has also shown promise in the treatment of autoimmune diseases. CD73 has been implicated in the development of autoimmune disorders, and by blocking its activity, the biosimilar may help to alleviate symptoms and improve disease outcomes.

Furthermore, Uprevstobart Biosimilar – Anti-CD73 mAb is also being studied for its potential in the treatment of inflammatory diseases, such as rheumatoid arthritis and psoriasis. CD73 has been shown to play a role in regulating inflammation, and by targeting it, the biosimilar may have anti-inflammatory effects.

In conclusion, Uprevstobart Biosimilar – Anti-CD73 mAb is a promising therapeutic antibody that has a similar structure and activity to the original Uprevstobart antibody. Its ability to target CD73 and inhibit its activity makes it a potential treatment for various types of cancer, autoimmune diseases, and inflammatory disorders. Further clinical studies are needed to fully evaluate its efficacy and safety in humans.